Dublin, Sept. 10, 2021 (GLOBE NEWSWIRE) -- The "Oral Proteins & Peptides Market Research Report by Drug Type, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The Global Oral Proteins & Peptides Market size was estimated at USD 971.92 Million in 2020 and expected to reach USD 1,096.79 Million in 2021, at a Compound Annual Growth Rate (CAGR) 13.18% to reach USD 2,043.61 Million by 2026.
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Oral Proteins & Peptides to forecast the revenues and analyze the trends in each of the following sub-markets:
- Based on Drug Type, the Oral Proteins & Peptides Market was studied across Calcitonin, Insulin, Linaclotide, Octreotide, and Plecanatide.
- Based on Application, the Oral Proteins & Peptides Market was studied across Bone Diseases, Diabetes, Gastric & Digestive Disorders, and Hormonal Disorders.
- Based on Region, the Oral Proteins & Peptides Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Oral Proteins & Peptides Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Oral Proteins & Peptides Market, including Allergan Plc., AstraZeneca PLC, Biocon Limited, Chiasma Inc., Generex Biotechnology Corp., Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Proxima Concepts Limited, Synergy Pharmaceuticals Inc., and Tarsa Therapeutics Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Oral Proteins & Peptides Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Oral Proteins & Peptides Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Oral Proteins & Peptides Market?
4. What is the competitive strategic window for opportunities in the Global Oral Proteins & Peptides Market?
5. What are the technology trends and regulatory frameworks in the Global Oral Proteins & Peptides Market?
6. What is the market share of the leading vendors in the Global Oral Proteins & Peptides Market?
7. What modes and strategic moves are considered suitable for entering the Global Oral Proteins & Peptides Market?
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in prevalence of chronic diseases
5.1.1.2. Rise in patient preference for oral drugs
5.1.1.3. Growing demand for effective drugs and technology
5.1.2. Restraints
5.1.2.1. High manufacturing costs and low bioavailability
5.1.3. Opportunities
5.1.3.1. Rise in oral peptide and protein therapeutics applications
5.1.3.2. Increase in R&D by pharmaceutical companies
5.1.4. Challenges
5.1.4.1. Concerns related to unwanted enzymatic degradation and inherent structural complexities
5.2. Porters Five Forces Analysis
6. Oral Proteins & Peptides Market, by Drug Type
6.1. Introduction
6.2. Calcitonin
6.3. Insulin
6.4. Linaclotide
6.5. Octreotide
6.6. Plecanatide
7. Oral Proteins & Peptides Market, by Application
7.1. Introduction
7.2. Bone Diseases
7.3. Diabetes
7.4. Gastric & Digestive Disorders
7.5. Hormonal Disorders
8. Americas Oral Proteins & Peptides Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Oral Proteins & Peptides Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand
10. Europe, Middle East & Africa Oral Proteins & Peptides Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Allergan Plc.
12.2. AstraZeneca PLC
12.3. Biocon Limited
12.4. Chiasma Inc.
12.5. Generex Biotechnology Corp.
12.6. Novo Nordisk A/S
12.7. Oramed Pharmaceuticals Inc.
12.8. Proxima Concepts Limited
12.9. Synergy Pharmaceuticals Inc.
12.10. Tarsa Therapeutics Inc.
13. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/dcr3ry
